SEC EDGAR CompanyFacts fact · reporting period
enGene Therapeutics Inc.: cashflow_investing
One fact, its scope and the complete path back to the official record.
Reported value
$-25.138M{"amount": -25138000, "concept": "us-gaap:NetCashProvidedByUsedInInvestingActivities", "currency": "USD"}- Entity
- enGene Therapeutics Inc.
- Metric
- cashflow_investing
- Period
- 2024-11-01 – 2025-10-31
- Status
- current
- Source
- SEC EDGAR CompanyFacts
Provenance
Source licenseUS-PD-17USC105
Retrieved2026-08-19T19:02:21.808587+02:00
Raw response SHA-256
f7bde1a401b286c74a2fd824ee1df541…Official-identifier path
https://factanker.com/fact/sec/cik-0001980845/cashflow-investing/2025-10-31 (CIK, metric, reporting date)History
- no predecessors — first report
Why this page exists
The UUID above is the stable citation anchor: it never changes, and corrections supersede rather than overwrite. Cite the URL and any reader — human or machine — can verify the value against the official filing.